97 related articles for article (PubMed ID: 12680624)
1. Secondary sulphonylurea failure: what pathogenesis is responsible?
Chen YN; Chen SY; Zeng LJ; Ran JM; Xie B; Wu MY; Wu YZ
Br J Biomed Sci; 2003; 60(1):9-13. PubMed ID: 12680624
[TBL] [Abstract][Full Text] [Related]
2. Progressive decrease of proinsulin secretion in sulphonylurea-treated type 2 diabetes.
Chen YN; Chen SY; Zeng LJ; Ran JM; Wu MY
Br J Biomed Sci; 2005; 62(1):5-8. PubMed ID: 15816204
[TBL] [Abstract][Full Text] [Related]
3. Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment.
Kumakura S; Iwamoto Y; Kuzuya T; Shiraishi I; Matsuda A; Saito T
Diabetes Res Clin Pract; 1995 Aug; 29(2):107-12. PubMed ID: 8591697
[TBL] [Abstract][Full Text] [Related]
4. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
[TBL] [Abstract][Full Text] [Related]
5. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.
Davies MJ; Metcalfe J; Day JL; Grenfell A; Hales CN; Gray IP
Diabet Med; 1994 Apr; 11(3):293-8. PubMed ID: 8033529
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes.
Panahloo A; Mohamed-Ali V; Andrés C; Denver AE; Yudkin JS
Metabolism; 1998 Jun; 47(6):637-43. PubMed ID: 9627359
[TBL] [Abstract][Full Text] [Related]
7. IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas.
Wegner M; Winiarska H; Bobkiewicz-Kozłowska T; Dworacka M
Cytokine; 2008 Jun; 42(3):312-6. PubMed ID: 18397831
[TBL] [Abstract][Full Text] [Related]
8. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
9. Increased secretion of 32,33 split proinsulin after intravenous glucose in glucose-tolerant first-degree relatives of patients with non-insulin dependent diabetes of European, but not Asian, origin.
Gelding SV; Andres C; Niththyananthan R; Gray IP; Mather H; Johnston DG
Clin Endocrinol (Oxf); 1995 Mar; 42(3):255-64. PubMed ID: 7758230
[TBL] [Abstract][Full Text] [Related]
10. Contribution of total and intact proinsulins to hyperinsulinism in subjects with obesity, impaired glucose tolerance or type 2 diabetes.
Blicklé JF; Sapin R; Andrès E
Diabetes Metab; 2000 Sep; 26(4):274-80. PubMed ID: 11011219
[TBL] [Abstract][Full Text] [Related]
11. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
Prigeon RL; Jacobson RK; Porte D; Kahn SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
[TBL] [Abstract][Full Text] [Related]
12. Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic beta-cell area.
Breuer TG; Menge BA; Banasch M; Uhl W; Tannapfel A; Schmidt WE; Nauck MA; Meier JJ
Eur J Endocrinol; 2010 Oct; 163(4):551-8. PubMed ID: 20679359
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin, proinsulin and proinsulin/insulin ratio in type 2 diabetic patients: as an index of beta-cell function or insulin resistance.
Kim NH; Kim DL; Choi KM; Baik SH; Choi DS
Korean J Intern Med; 2000 Dec; 15(3):195-201. PubMed ID: 11242807
[TBL] [Abstract][Full Text] [Related]
14. [Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)].
Jedynasty K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R
Pol Arch Med Wewn; 1998 Jun; 99(6):442-51. PubMed ID: 10085698
[TBL] [Abstract][Full Text] [Related]
15. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
17. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
18. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
[TBL] [Abstract][Full Text] [Related]
19. Hyperproinsulinemia is not a characteristic feature in the offspring of patients with different phenotypes of type II diabetes.
Vauhkonen IK; Niskanen LK; Mykkänen L; Haffner SM; Uusitupa MI; Laakso M
Eur J Endocrinol; 2000 Aug; 143(2):251-60. PubMed ID: 10913945
[TBL] [Abstract][Full Text] [Related]
20. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
